Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2022 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to...
December 20, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 16, 2021 08:59 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 01, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 22, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 10, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
September 09, 2021 07:32 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Issues Letter to Shareholders

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
September 08, 2021 07:32 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
August 30, 2021 07:32 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND Fourth FDA Division to Clear TSC IND CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...
June 30, 2021 07:35 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...